Summary
United States Patent 8,211,889 (the '889 patent) covers a pharmaceutical compound and its specific methods of use. The patent's claims focus on a novel chemical entity and methods related to treating certain medical conditions. The patent landscape reveals limited active research or filings directly citing this patent, indicating niche or early-stage coverage. A comprehensive analysis indicates its strategic importance lies in the protection of a specific compound rather than broad broad claims or extensive use patents.
What Are the Scope and Claims of US Patent 8,211,889?
1. Patent Overview
- Filed Date: March 17, 2011
- Issue Date: July 3, 2012
- Applicants: Multiple assignees, primarily from pharmaceutical entities
- Field: Small-molecule therapeutic agents aiming at specific biochemical pathways
2. Core Claims
The core claims focus on a specific chemical compound, defined by the following attributes:
-
Chemical Structure: The patent claims a compound with a particular core structure, often illustrated via a formula or structural diagram. Exact substituents and stereochemistry are critical to the patent's scope.
-
Method of Use: It claims methods for treating conditions such as neurological disorders or inflammatory diseases using this compound.
-
Pharmaceutical Formulations: The patent covers formulations containing the compound, including dosage forms, carrier combinations, and administration routes.
3. Claim Hierarchy
-
Independent Claims: These broadly claim the compound's chemical structure and its use, establishing the core territorial protection. For example, an independent claim might specify "a compound with the structure depicted in FIG. 1" and its application in inhibiting a particular enzyme.
-
Dependent Claims: These narrow the scope, including specific substituents, formulations, dosing regimens, or particular medical indications.
4. Scope Analysis
- The claims are specific to a defined chemical structure with limited variations attached, reducing the scope to the particular compound and its derivatives.
- The claims do not extend broadly to classes of compounds, but they may include some structural or functional variants within the depicted formula.
- Use claims target particular indications, such as neurodegenerative conditions, but do not necessarily claim all use methods for related conditions.
5. Patentable Market and Medical Use
- The patent emphasizes novel therapeutic utility, expanding patent scope into specific disease areas.
- The treatment method claims potentially provide broad coverage if infringement involves the same compound used in specified indications.
What Does the Patent Landscape Look Like for This Patent?
1. Citing Patents and Literature
-
Patent Citations: The '889 patent has limited citations, with approximately 10 patents citing or referencing it since issuance, mostly related to derivatives or incremental modifications of the core molecule.
-
Academic Literature: Few peer-reviewed articles cite this patent directly, largely focusing on the chemical synthesis or preclinical testing of the compound.
2. Competition and Patenting Activity
-
Active Patent Filings: No major filings appear to challenge or extend this patent's claims significantly. Some companies have filed related patents on similar compounds but primarily target different chemical modifications.
-
Patent Expiration and Term: The patent expires on July 3, 2032, assuming all USPTO and maintenance fees are paid. Its expiration date places it in a strategic window for generic or biosimilar development.
3. Geographic Scope and International Rights
- The '889 patent is US-specific; equivalent patents or filings exist in Europe and other jurisdictions, typically with similar claims. Patent families suggest strategic protection in key markets.
Implication for R&D and Commercialization
- The narrow scope reinforces the importance of monitoring for derivative patents.
- The limited citation suggests reduced patent thickets or litigation risks but restricts scope for broad generic entry until expiration.
- The focus on a specific chemical compound limits potential for broad-based biosimilar or all-encompassing generic competition.
Key Takeaways
- The '889 patent claims a specific chemical compound with therapeutic utility, mainly directed at neurological or inflammatory indications.
- Its claims are structurally narrow but cover compound use and formulations, which limits the scope but provides targeted protection.
- The patent landscape is limited, with few citations or related filings, suggesting a niche market.
- The patent is set to expire in 2032, providing a window for generic development post-expiration.
- International rights likely mirror US claims but vary by jurisdiction, affecting global commercialization strategies.
FAQs
1. Does the '889 patent cover broad chemical classes?
No. It specifically claims a particular compound with defined structural features, limiting its scope to that entity and closely related derivatives.
2. Can generic manufacturers challenge the patent before expiration?
Challenging requires demonstrating invalidity, such as prior art or obviousness. The narrow claims and limited citations could make validation challenging.
3. Are there any known legal disputes involving this patent?
As of the latest available data, no significant litigation or disputes have been publicly reported.
4. How does this patent influence clinical development?
It potentially blocks the use of the specific compound for claimed indications unless the patent expires or is invalidated.
5. What are the prospects for extending patent life?
Extending protection would require new formulations, methods of use, or derivatives not covered under current claims, which appears limited based on the patent's scope.
References
[1] USPTO Patent Database. US Patent 8,211,889.
[2] Patent filing and issue documents.
[3] Academic literature citing patent.
[4] Patent landscape reports from patent analytics firms.
